Quick Answer
Theriva Biologics, Inc. reported Net Income Loss of -$18.35 million for the year ending 2023.
- Theriva Biologics, Inc. showed an increase of +6.8% in Net Income Loss from 2022 to 2023.
- This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2024.
- XBRL data for this metric is available from 2010 to 2023 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: -$1.93 million | Q1 2013: -$2.23 million | Q2 2013: -$2.50 million | Q3 2013: -$3.37 million | Q4 2013: -$4.23 million | Q1 2014: -$3.84 million | Q2 2014: -$4.56 million | Q3 2014: -$4.91 million | Q4 2014: -$6.48 million | Q1 2015: -$12.36 million | Q2 2015: -$13.62 million | Q3 2015: -$7.51 million | Q4 2015: -$11.30 million | Q1 2016: -$11.08 million | Q2 2016: -$5.76 million | Q3 2016: -$8.49 million | Q4 2016: -$2.47 million | Q1 2017: -$3.06 million | Q2 2017: -$4.32 million | Q3 2017: -$10.93 million | Q4 2017: $2.81 million | Q1 2018: -$2.32 million | Q2 2018: -$4.20 million | Q3 2018: -$3.68 million | Q4 2018: -$3.19 million | Q1 2019: -$3.51 million | Q2 2019: -$3.53 million | Q3 2019: -$5.12 million | Q1 2020: -$2.96 million | Q2 2020: -$2.87 million | Q3 2020: -$2.10 million | Q1 2021: -$2.54 million | Q2 2021: -$3.20 million | Q3 2021: -$3.27 million | Q1 2022: -$4.27 million | Q2 2022: -$4.48 million | Q3 2022: -$4.49 million | Q3 2023: -$3.30 million.
- Over the full 14 years of available data (2010 to 2023), Theriva Biologics, Inc.'s Net Income Loss has declined by 972.4%.
- Historical annual values: Fiscal year 2023: -$18.35 million | Fiscal year 2022: -$19.69 million | Fiscal year 2021: -$14.27 million | Fiscal year 2020: -$10.04 million | Fiscal year 2019: -$15.30 million | Fiscal year 2018: -$13.37 million | Fiscal year 2017: -$15.17 million | Fiscal year 2016: -$27.26 million | Fiscal year 2015: -$43.74 million | Fiscal year 2014: -$19.78 million | Fiscal year 2013: -$12.32 million | Fiscal year 2012: -$17.07 million | Fiscal year 2011: -$8.15 million | Fiscal year 2010: -$1.71 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: